The targeted protein degradation market size is likely to be worth USD 0.48 billion in , and is projected to reach worth USD 6.94 billion by , growing at an annualized rate (CAGR) of 32% during the forecast period -.
Lianhe Aigen Product Page
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis, grants analysis, patent analysis, publication analysis, clinical trial analysis, market impact analysis, partnerships and collaborations, and funding and investments analysis. In addition, we have provided targeted protein degradation market forecast along with sales forecast of drugs which are being evaluated in later stages of clinical development. Driven by the availability of innovative technology platforms, lucrative partnership, funding and encouraging clinical trial results, along with continuous research and development efforts, the market is poised to grow in the long-run, as several product candidates are expected to receive marketing approval in the coming decade.
Over the years, conventional drug discovery approaches, such as small molecule inhibitors, focused on inhibiting the activity of particular protein to relieve disease symptoms, have faced several challenges. These inhibitors were unable to bind to several potential targets due to their intracellular location and absence of suitable binding pockets. In fact, the existing inhibitors were able to bind to even less than 20% of all disease-causing proteins, leaving 80% of them as undruggable targets. However, with increasing understanding of cellular mechanisms and proteomics, researchers have developed an unconventional approach; targeted protein degraders go beyond inhibition and serve as a promising alternative in the quest for more effective therapies.
Targeted protein degradation is a novel drug discovery approach that leads to elimination of disease-causing proteins by harnessing cellular machinery within the small molecules. In addition, the modalities responsible for breakdown of proteins are known as targeted protein degraders. Protein degraders are bifunctional small molecules that recruit E3 ubiquitin ligases to the protein of interest and mediate its ubiquitination and subsequent proteolysis by the proteasome, thereby resulting in degradation of a specific protein. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them. This process has been shown to be robust, more sensitive and can regulate cellular functions in an effective manner, since it is independent of any attachment with other sites.
Further, in recent years, targeted protein degraders have emerged as a popular therapeutic modality due to the various advantages offered by them, including specificity, stability and minimal off-side effects. Additionally, it is worth noting that these degraders offer broad applicability and can gain selectivity for their protein targets by optimizing the linker length and stabilizing the ternary complexes.
Owing to these advantages, there are several types of degraders that are currently being evaluated under different stages of pre-clinical and clinical development, including Proteolysis-targeting Chimeras (PROTACs), Selective Estrogen Receptor Degraders (SERDs), Selective Androgen Receptor Degraders (SARDs), Endosome-targeting Chimeras (ENDTACs), Photochemically-targeting Chimeras (PHOTACs), Lysosome-targeting Chimeras (LYTACs), DUB (Deubiquitinase) inhibitors, hydrophobic tags, Immunomodulatory Imide Drugs (IMiDs), molecular glues, Selective Hormone Receptor Degraders (SHRDS) and others, for various diseases, especially cancer. Cancer is one of the leading causes of deaths worldwide. In fact, around 10 million cancer related deaths were reported in . Moreover, it is estimated that, by the end of , over 35 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on the affected individuals, their families, communities as well as the national health systems.
Therefore, several start-ups and big pharma players have entered the targeted protein degradation market, offering novel targeted protein degradation technologies leading to the development of more potent, pharmacologically different and target-specific degraders. Driven by the growing demand for selective and efficacious treatments, the targeted protein degradation market is poised to witness substantial growth during the forecast period.
The market report presents an in-depth analysis of various targeted protein degradation developers and technology providers in this domain, across different segments, as defined in the below table:
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the targeted protein degradation market, over the forecast period. Based on multiple relevant parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period.
The targeted protein degradation market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of degrader (SERD, PROTAC and Molecular Glue), target indication (Breast Cancer and Multiple Myeloma), key geographical regions (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)) and sales forecast. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (arranged based on the seniority level):
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this targeted protein degradation market report are in USD, unless otherwise specified.
The global targeted protein degradation market is segmented into SERDs, PROTACs and molecular glues, based on the type of degrader. Owing to the approval of elacestrant (brand name ORSERDU), an orally bioavailable SERD for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in January , the market segment for SERDs is likely to capture the highest current targeted protein degradation market share (~50%). The trend is unlikely to change in the coming years owing to anticipated approvals of more SERD candidates as compared to other degraders.
This section segments the targeted protein degradation market across different target indications, including breast cancer and multiple myeloma. Currently, breast cancer holds the maximum share in the market and this trend is unlikely to change in the future as well. This can be attributed to the rapidly increasing incidence of breast cancer, with over 12.5% of all newly diagnosed cases, making it as one of the most prevalent forms of cancer worldwide. Further, the market for targeted protein degradation therapies intended for the treatment of multiple myeloma is estimated to grow at an annualized rate (CAGR) of 26% during the forecasted period. It is the second most common hematologic malignancy worldwide, with an estimated annual incidence of 7.1 per 100,000 people.
The company is the world’s best PROTAC Linker Pharma Service supplier. We are your one-stop shop for all needs. Our staff are highly-specialized and will help you find the product you need.
This segment highlights the distribution of targeted protein degradation market across key geographical regions, including (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)). It is worth highlighting that North America captures close to 83% of the current targeted protein degradation market. Further, the market in Asia-Pacific is expected to grow with a CAGR of more than 60%. This is primarily due to the increasing number of biopharmaceutical start-ups in this region, and likely drug approvals in the region for the treatment of various oncological indications.
The Targeted Protein Degradation Market - Industry Trends and Global Forecasts, till : Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Key Geographical Regions (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)) and Sales Forecast market report features an extensive study of the current market landscape, market size, market share, market analysis, market forecast and future opportunities for the targeted protein degradation companies. The targeted protein degradation market report highlights the efforts of several drug developers engaged in this rapidly emerging market segment of the pharmaceutical industry. Key takeaways of market research report are briefly discussed below.
Currently, over 90 drug developers are involved in the development of targeted protein degradation therapies for various oncological indications, especially breast cancer, solid tumour and prostate cancer. The market landscape features a mix of large, mid-sized and small firms. Additionally, players such as Arvinas, Monte Rosa Therapeutics and Lycia Therapeutics are revolutionizing the targeted protein degradation therapies research and development and driving impactful innovations in the healthcare domain. It is interesting to note that Arvinas is the first company in this domain to develop a PROTAC (Vepdegestrant / ARV-471), first-ever-modality of its class, being investigated in phase III studies. PROTACs hold great potential due to their ability to selectively target proteins, reducing their impact on non-disease-related proteins, offering high specificity. Further, majority of the PROTACs have been designed to be taken orally, easing the administration process for patients.
Presently, around 80 companies are involved in offering various novel and advanced targeted protein degradation technologies. The degraders that are being developed with the help of these technologies include PROTACs, molecular glues, DUB inhibitors, bifunctional degraders, LYTACs, antibody drug conjugate-based degraders and monovalent degraders. It has been observed that the majority of the targeted protein degraders developed using these technologies follow ubiquitin proteasomal pathway. Further, most of the targeted protein degradation technologies are capable of target identification, ligand optimization and ligase selection.
It is worth mentioning that some of the technologies employ advanced tools, such as CADD for designing and analyzing 3D-structure of protein leading to the development of more precise and potent degraders. We believe that targeted protein degradation technologies are poised to play a significant role in shaping the future market landscape, by enabling the development of novel therapeutic modalities for targets that were previously considered undruggable.
Targeted protein degraders ability to degrade the undruggable targets selectively while minimizing off-side toxicity, along with offering broad applicability is anticipated to drive the demand for these therapies for treating oncological and non-oncological disorders over time. In order to cater to this growing demand, several alliances have been forged by various stakeholders in the past few years. These partnerships have enabled the stakeholders to enhance their existing capabilities in terms of drug and technology portfolios to consolidate their presence in the targeted protein degradation industry. In fact, the partnership activity has witnessed a CAGR of ~23%, during the period, -. It is worth mentioning that research and development emerged as the most common type of partnership model adopted by the stakeholders in this domain.
In addition, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed targeted protein degradation companies to progress their R&D efforts in this domain. It is important to highlight that over USD 13.5 billion has been raised by the companies in this domain, since . For instance, Kymera Therapeutics has raised a total of USD 517 million till date across four rounds of funding.
It is worth noting that more than 985 patents have been filed / granted related to targeted protein degradation in the last five years. Moreover, over 385 articles related to targeted protein degradation have been published in the last five years. Further, there has been a notable rise in the number of clinical trials in this domain with around 250 clinical trials being registered in the past few years; of these, most of the clinical trials are actively recruiting patients to evaluate targeted protein degradation therapies for breast cancer, B cell lymphoma and others. Driven by the ongoing pace of advancements in this field, growing collaborations, ample financial support from investors, rising number of patents and research articles, and encouraging clinical trial results, the targeted protein degradation market size is likely to witness significant growth during the forecast period.
Presently, companies based in North America capture half of the targeted protein degradation market share. Driven by the rising interest of stakeholders in the field of targeted protein degradation, the market in North America is anticipated to grow at a CAGR of 25.4%, during the forecast period, -. A number of factors contribute to the region’s dominance in this industry which include the presence of several well-established and big pharma companies with diverse experience in research and development of drugs.
Moreover, the advanced healthcare infrastructure in North America enable drug developers to conduct extensive clinical trials required to meet the stringent regulatory guidelines of the drug approval bodies. However, in terms of market growth, the targeted protein degradation market in Asia-Pacific is likely to grow at a relatively faster pace in the long term, primarily due to likely approval of several degraders and affordable price of treatments in this region.
The rising incidence of cancer has contributed towards development of novel entities for cancer treatment. Owing to this, various researchers and stakeholders are putting in efforts to evaluate different types of modalities. One such modality is targeted protein degraders that has the likely potential to be utilized for treatment of oncological indications. Several ongoing technological advancements in terms of novel PROTAC platforms and molecular glue technologies can pave the way for development of precise and stable degraders. Additionally, the potential of targeted protein degraders in selectively modulating the complex undruggable targets by harnessing cells own machinery, can contribute towards the growth of this market. Furthermore, most of the degraders can be formulated as oral medications, allowing easy administration by patients that can aid in greater adoption of these therapies in the coming years.
Examples of the key players involved in the development of targeted protein degraders (the complete list of players is available in the full report) include (in alphabetic order) Arvinas, AstraZeneca, BeiGene, Bristol-Myers Squibb, C4 Therapeutics, Eisai Therapeutics, InnoCare Pharma, Kangpu Biopharmaceuticals, Kintor Pharmaceutical, Loxo Oncology, Medivir, Monte Rosa Therapeutics, Olema Oncology, Radius Health, Ranok Therapeutics, Roche, Sanofi and Zentalis Pharmaceuticals. This global targeted protein degradation market research report includes an easily searchable excel database of all the companies that are developing targeted protein degradation therapies.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different geographies. Amongst other elements, the market report includes:
Several recent developments have taken place in the field of targeted protein degradation. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Want more information on Advanced Intermediates Service? Feel free to contact us.